A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without bevacizumab, in adults with advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors, non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metastatic Hepatocellular Carcinoma
• Local Advanced Hepatocellular Carcinoma
• Alpha-fetoprotein (AFP)-Producing Gastric Cancer
• Extragonadal Yolk Sac Tumors
• Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

BeOne Medicines

Last updated on ClinicalTrials.gov

September 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites